Vergoeding 2019-2023 voor ATC-subgroep J05AF : Nucleoside en nucleotide reverse-transcriptaseremmers
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| J05AF01 Zidovudine (Retrovir ®) | 19.823 | 13.729 | 18.596 | 16.781 | 14.332 |
| J05AF05 Lamivudine (Epivir ®) | 424.470 | 302.120 | 229.880 | 166.360 | 155.400 |
| J05AF06 Abacavir (Ziagen ®) | 385.420 | 303.220 | 257.700 | 217.410 | 183.240 |
| J05AF07 Tenofovirdisoproxil (Viread ®) | 994.490 | 876.930 | 676.300 | 638.080 | 646.900 |
| J05AF08 Adefovir | 246.130 | 191.670 | 159.190 | 126.560 | 46.571 |
| J05AF09 Emtricitabine (Emtriva ®) | 50.287 | 52.636 | 44.421 | 40.896 | 41.394 |
| J05AF10 Entecavir (Baraclude ®) | 1.484.400 | 1.643.000 | 1.326.500 | 1.443.600 | 1.876.900 |
| J05AF11 Telbivudine | 20.327 | 2.504 | . | . | . |
| J05AF13 Tenofoviralafenamide (Vemlidy ®) | 1.101.300 | 1.595.600 | 1.790.200 | 1.964.800 | 2.294.500 |
| Totaal | 4.726.647 | 4.981.409 | 4.502.787 | 4.614.487 | 5.259.237 |